drugset / Trial / NCT05590260

Summary

PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken 6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site, will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks postpartum, the incidence of achieving a non-anemic state (defined as Hb ≥11 g/dL) will be greater among women receiving a single-dose infusion of IV iron than among women receiving standard care with oral iron.

Timeline

Start
2023-05-30
Primary completion
2025-03-10
Completion
2025-07-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 20 mg/kg Intravenous
Comparator elemental iron Unknown 60 mg Oral
Comparator folic acid Other / unclassified 400 ug

Indications

No indication recorded.